Catalent, Inc. (NYSE:CTLT) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC cut its position in shares of Catalent, Inc. (NYSE:CTLT) by 53.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 882 shares of the company’s stock after selling 993 shares during the quarter. Farther Finance Advisors LLC’s holdings in Catalent were worth $53,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CTLT. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent during the second quarter worth about $42,000. Longfellow Investment Management Co. LLC boosted its position in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the period. GAMMA Investing LLC boosted its position in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Catalent by 1,400.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company’s stock worth $91,000 after buying an additional 1,400 shares during the period. Finally, Federated Hermes Inc. boosted its position in shares of Catalent by 456.6% in the second quarter. Federated Hermes Inc. now owns 2,833 shares of the company’s stock worth $159,000 after buying an additional 2,324 shares during the period.

Catalent Trading Down 0.2 %

Shares of CTLT opened at $59.15 on Thursday. The company has a market capitalization of $10.74 billion, a P/E ratio of -26.17, a P/E/G ratio of 2.36 and a beta of 1.16. Catalent, Inc. has a one year low of $34.92 and a one year high of $61.20. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a 50-day moving average price of $59.89 and a 200 day moving average price of $58.16.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business earned ($0.10) EPS. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Sell-side analysts forecast that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CTLT has been the subject of several analyst reports. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research report on Wednesday, November 6th. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. Based on data from MarketBeat, Catalent has an average rating of “Hold” and an average price target of $59.83.

Insiders Place Their Bets

In other Catalent news, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.31% of the stock is currently owned by company insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.